Anti-TNF-Alpha-Adalimumab Therapy Had Time Lag of Improvement in Synovial Hypertrophy Compared to Rapid Response in Power Doppler Synovial Vascularity.

Ying-Chou ChenChi-Hua KoJia-Feng ChenChung-Yuan HsuWen-Chan ChiuTien-Tsai Cheng

Published in: Mediators of inflammation (2017)

Composite US markers of synovial hypertrophy correlate significantly to the DAS28 score and ESR/CRP in adult RA. The time needed for synovial hypertrophy to decrease may be up to 3-6 months after adalimumab therapy. Switching to biological therapy before 3-6 months is inappropriate and ineffective.

Keyphrases

rheumatoid arthritis
disease activity
juvenile idiopathic arthritis
young adults
ulcerative colitis
cell therapy
ankylosing spondylitis
replacement therapy